SCHEMBL7753501

SCHEMBL7753501

Cc1ccc(S(=O)(=O)N(N)Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.53
MCOLN3 Q8TDD5 1/20 0.53
CA12 O43570 3/20 0.52
CA9 Q16790 3/20 0.52
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
CA3 P07451 1/20 0.52
CA6 P23280 1/20 0.52
CA5A P35218 1/20 0.52
CA7 P43166 1/20 0.52
CA5B Q9Y2D0 1/20 0.52
C5AR1 P21730 2/20 0.50
GAA P10253 2/20 0.50
AGER Q15109 1/20 0.50
KEAP1 Q14145 1/20 0.47
NFE2L2 Q16236 1/20 0.47
GLA P06280 1/20 0.47
TLR9 Q9NR96 1/20 0.45
CNR2 P34972 2/20 0.45
KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dichloramine-T SCHEMBL151251 0.82 MAPT (0.57) MAPTMCOLN3CA12CA9CA1
SCHEMBL4402780 0.82 MAPT (0.57) MAPTMCOLN3CA12CA9CA1
SCHEMBL24770891 0.82 CA12 (0.62) MAPTMCOLN3CA12CA9CA1
SCHEMBL5852578 0.80 MAPT (0.61) MAPTMCOLN3CA12CA9CA1
Dichloramine-T SCHEMBL4275006 0.80 MAPT (0.55) MAPTMCOLN3CA12CA9CA1
SCHEMBL420472 0.80 MAPT (0.61) MAPTMCOLN3CA12CA9CA1
SCHEMBL29290107 0.78 AGER (0.55) MAPTMCOLN3CA12CA9CA1
SCHEMBL5805376 0.77 APOBEC3G (0.54) CA12CA9CA1CA2CA3
SCHEMBL7946990 0.77 MAPT (0.62) MAPTMCOLN3CA12CA9CA1
SCHEMBL6990099 0.77 MAPT (0.61) MAPTMCOLN3CA12CA9CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230175195-A1 PLASMA COATING TREATMENT METHOD FOR INHIBITING BIOLOGICAL PATHOGEN TRANSFER MOLECULAR PLASMA GROUP S.A. (LU) 2023-06-08 US disclosed
EP-0833820-B1 BENZISOXAZOLE AND INDAZOLE DERIVATIVES AS ANTIPSYCHOTIC AGENTS AVENTIS PHARMA INC (US) 2001-02-14 EP disclosed
US-6008348-A TREATING A 1-TOSYLATED INDAZOL-3-YL PIPERAZINE DERIVATIVE WITH CONCENTRATED HYDROCHLORIC ACID TO PRODUCE THE DETOSYLATED INDAZOL-3-YL PIPERAZINE COMPOUND OF GIVEN FORMULA HOECHST MARION ROUSSEL, INC. (US) 1999-12-28 US disclosed
US-5965554-A PIPERAZINYLBENZISOXAZOLE DERIVATIVES HOECHST MARION ROUSSEL, INC. (US) 1999-10-12 US disclosed
US-5852022-A Antipsychotic agents, composition and method of use HOECHST ROUSSEL PHARMACEUTICALS INC. (US) 1998-12-22 US disclosed
EP-0833820-A1 BENZISOXAZOLE AND INDAZOLE DERIVATIVES AS ANTIPSYCHOTIC AGENTS HOECHST MARION ROUSSEL, INC. (US) 1998-04-08 EP disclosed
WO-1996039397-A1 BENZISOXAZOLE AND INDAZOLE DERIVATIVES AS ANTIPSYCHOTIC AGENTS HOECHST MARION ROUSSEL, INC. (US) 1996-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230175195-A1 PLASMA COATING TREATMENT METHOD FOR INHIBITING BIOLOGICAL PATHOGEN TRANSFER TFPI, TTPA, CD4 MAPT 369/4885MCOLN3 4671/4885CA12 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.